GlassScriptPhysician profile
Beverly Dicerbo
NPI 1720139033
$2,731.67
in general payments reported to CMS, 2019-2025
34 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $853 · 2022: $562 · 2023: $391 · 2024: $419 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,217 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,216.80 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $452.64 | 2021-2025 | |
| Janssen Biotech, INC. | $339.63 | 2021-2025 | Erleada, Balversa, Rybrevant |
| Incyte Corporation | $215.54 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Seagen INC. | $173.18 | 2021-2023 | Padcev |
| Pharmacyclics LLC, An Abbvie Company | $162.53 | 2022-2023 | Imbruvica |
| Genentech USA, INC. | $156.84 | 2022-2024 | Phesgo, Kadcyla, Lunsumio |
| Astellas Pharma US INC | $138.46 | 2021-2022 | |
| Eisai INC. | $102.93 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.66 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.16 | 2021-2024 | Fruzaqla, Aralast |
| Lilly USA, LLC | $60.86 | 2021-2025 | Verzenio, Jaypirca |
| Dendreon Pharmaceuticals LLC | $59.73 | 2025 | Provenge |
| Astrazeneca Pharmaceuticals LP | $59.60 | 2021 | |
| Glaxosmithkline, LLC. | $59.58 | 2023-2024 | Zejula, Jemperli, Benlysta |
| E.R. Squibb & Sons, L.L.C. | $55.98 | 2021-2023 | Opdivo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $45.80 | 2022-2023 | |
| Amgen INC. | $45.51 | 2021-2023 | Lumakras |
| Celgene Corporation | $43.45 | 2021 | |
| Aveo Pharmaceuticals, INC. | $42.19 | 2022-2024 | |
| Pharmacosmos Therapeutics INC. | $37.39 | 2023-2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $37.24 | 2021 | |
| Merck Sharp & Dohme LLC | $37.03 | 2023-2025 | Keytruda |
| Servier Pharmaceuticals LLC | $35.57 | 2024 | |
| Daiichi Sankyo INC. | $33.80 | 2021-2024 | Enhertu |
| Puma Biotechnology, INC. | $29.84 | 2021 | |
| Abbvie INC. | $27.44 | 2021-2025 | |
| Mirati Therapeutics, INC. | $18.18 | 2023 | Krazati |
| Karyopharm Therapeutics INC. | $17.53 | 2025 | Xpovio |
| Kite Pharma, INC. | $17.38 | 2023 | Yescarta |
| Revance Therapeutics, INC. | $16.78 | 2025 | Daxxify |
| Geron Corporation | $16.42 | 2025 | Rytelo |
| Tersera Therapeutics LLC | $15.92 | 2025 | Zoladex |
| Sobi, INC | $14.64 | 2025 | |
| Beigene USA, INC. | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Dicerbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.